Tirbanibulin in adults with facial actinic keratosis: seeing if it improves appearance and skin feel

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study of adults with facial actinic keratosis who are already using tirbanibulin. Participants complete online surveys at the start and at day 57 to report changes in overall appearance, skin texture, and skin quality. The study aims to describe real‑world effectiveness in a 57‑day observation period without assigning a treatment. Data are collected via self-report, focusing on patients’ perceptions of their facial skin after tirbanibulin treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with AK on the face.
* Has clinically typical, visible, and discrete 4-12 AK lesions on the face.
* Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face.
* Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin.
* Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration.
* Able to read and write in English.
* Provide consent to participate in the study.
* Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study.

Exclusion Criteria:

* Patients with any dermatological condition of the face that could interfere with clinical evaluations.
* Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area.
* Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
* Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study.
* Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.

Where it's running

• Ablon Skin Institute and Research Center
  Manhattan Beach, California, United States Recruiting
• Dermatology & Laser Center of Charleston
  Charleston, South Carolina, United States Recruiting

Study contacts

• Principal investigator: Todd Schlesinger, MD — Avant Health LLC
• Study coordinator: Siva Narayanan, PhD, MPhil, MHS, MSc
• Email: info@avant-health.com
• Phone: 301-799-AVANT

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multimodal Laser Treatment for Photodamaged Facial Skin

  A randomized split-face study tests a combination of three lasers and light therapy to improve sun-damaged facial skin and potentially help prevent skin cancer in adults with actinic keratosis.

  Recruiting Bispebjerg Hospital · Copenhagen NV · NCT07789002

• Pharmacokinetic test of reformulated Levulan Kerastick for actinic keratosis on forearms or face

  This study tests how the reformulated Levulan Kerastick behaves in the body when used on actinic keratosis lesions on the arms or face, followed by blue-light treatment.

  Recruiting Phase 1 Sun Pharmaceutical Industries Limited · College Station, Texas · NCT07729579

• Photoprotection with Anthelios Fluide 100 KA+ UVMune 400 for people with multiple actinic keratoses

  This trial will see if daily use of the sunscreen Anthelios Fluide 100 KA+ UVMune 400 together with good sun-protection habits helps protect people aged 60 and older who have multiple actinic keratoses.

  Recruiting Cosmetique Active International · Camperdown, New South Wales · NCT07335003

• HW211026 ointment for facial actinic keratosis

  This will test a new topical ointment, HW211026, on the face to see if it is safe and how the body absorbs and responds to it in people with actinic keratosis.

  Recruiting Phase 1 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Shanghai · NCT07318675

• Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients

  This trial tests whether applying a 5% niacinamide cream daily, in addition to sunscreen, can reduce actinic keratoses and new skin cancers in adults who have had an organ transplant.

  Recruiting at 2 sites Early Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania and 1 other locations · NCT07286318

• Topical tirbanibulin (Klisyri) for actinic keratoses with downward-directed growth

  We will test whether applying topical tirbanibulin (Klisyri) can reduce downward-directed proliferation of actinic keratoses on the scalp or face in adults.

  Recruiting CentroDerm GmbH · Wuppertal, North Rhine-Westphalia · NCT06648447

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.